Early detection program for subtle memory and thinking changes in older adults
German: COGSCREEN II: Früherkennung Kognitiver Störungen Durch Screeningverfahren Von Haus- Und Fachärzten Bei Senioren in Deutschland English: COGSCREEN II: Early Detection of Cognitive Impairment Through Screening Procedures by General Practitioners and Specialists in Older Adults in Germany (DAC AccDx Munich Site)
NA · Ludwig-Maximilians - University of Munich · NCT07466394
This project will test a targeted cognitive screening program to find early memory and thinking problems in people aged 60 and older who notice changes.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich (other) |
| Locations | 1 site (München) |
| Trial ID | NCT07466394 on ClinicalTrials.gov |
What this trial studies
This interventional program offers targeted cognitive screening to older adults with subjective cognitive decline or mild cognitive impairment to detect early Alzheimer's-related changes. Participants at LMU Klinikum undergo standardized cognitive tests and may be offered biomarker evaluation such as cerebrospinal fluid testing when indicated to identify an AD-typical profile. The aim is to implement a standardized pathway for identifying minimal cognitive decline in routine care so that at-risk individuals can be referred for monitoring, preventive measures, or emerging disease-modifying treatments. Enrollment includes people aged 60 or older who can consent and excludes those with a prior dementia diagnosis or sensory impairments that prevent testing.
Who should consider this trial
Good fit: Ideal candidates are adults aged 60 or older who can give informed consent and who report subjective cognitive decline or have mild cognitive impairment without a prior dementia diagnosis.
Not a fit: Patients who already have a dementia diagnosis, who cannot hear or see well enough for testing, or who are under 60 are unlikely to benefit from this program.
Why it matters
Potential benefit: If successful, this approach could help people with early memory changes get diagnosed sooner, access appropriate monitoring or treatments earlier, and plan for the future.
How similar studies have performed: Research using cognitive screening plus biomarkers has shown promise for identifying prodromal Alzheimer's in specialized settings, but routine, targeted early-detection systems are not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female ≥ 60 years of age at the time of consent * Able to understand and voluntarily sign an informed consent according to the judgment of the practice team Exclusion Criteria: * Subjects who are unable to hear or see well enough to complete the assessments * Prior diagnosis of dementia (with or without evidence of pathology) as documented in the medical record and/or diagnosed by a physician
Where this trial is running
München
- Klinik für Psychiatrie und Psychotherapie am LMU Klinikum — München, Germany (RECRUITING)
Study contacts
- Study coordinator: Prof. Dr. Robert Perneczky
- Email: robert.perneczky@med.uni-muenchen.de
- Phone: +89440055772
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer's Disease